Nordic Nanovector ASA, of Oslo, Norway, said its investigational new drug application for a new phase I study of Betalutin in a second non-Hodgkin lymphoma indication is now open with the FDA. The company plans to investigate Betalutin in relapsed diffuse large B-cell lymphoma patients who are ineligible for stem cell transplant. Betalutin comprises a tumor-seeking anti-CD37 antibody conjugated to a low-intensity radionuclide (lutetium-177).